Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws

Scott Olson

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion.

Eli Lilly (NYSE:LLY) is expected to pay around $1 billion upfront for the privately owned Scorpion, according to a